#aacr19: Deconvoluting Tumor Heterogeneity Using Single-Cell Genomics

Posted on March 29, 2019 by kuhnadmin

Presenter James B. Hicks, PhD. University of Southern California, Los Angeles, CA Description Cancer is a genetic disease that evolves over time and in response to treatment, whether in model systems or in the setting of human disease. It is therefore imperative to create tools to assess genomic and transcriptomic complexity in order to understand …

Continue reading “#aacr19: Deconvoluting Tumor Heterogeneity Using Single-Cell Genomics”

#AACR19: Genomic instability as a marker of poor prognosis in advanced prostate cancer: Subclonal insights from whole-genome sequencing of single circulating tumor cells

Posted on March 29, 2019 by kuhnadmin

Presenters: Paymaneh D. Malihi1, Ryon P. Graf2, Carmen Ruiz Velasco1, Anand Kolatkar1, Angel E. Rodriguez2, Jerry Lee2, Ramsay Sutton2, Paul G. Corn3, Christopher J. Logothetis3, Ana M. Aparicio3, James Hicks1, Ryan Dittamore2, Amado J. Zurita3, Peter Kuhn1.  1University of Southern California, Los Angeles, CA; 2EPIC Sciences, San Diego, CA; 3MD Anderson Cancer Center, Houston, TX Abstract: A …

Continue reading “#AACR19: Genomic instability as a marker of poor prognosis in advanced prostate cancer: Subclonal insights from whole-genome sequencing of single circulating tumor cells”

#AACR19: Morphologic and genomic characterization of circulating tumor cells in patients with ERBB2 mutant HER2 non-amplified metastatic breast cancer treated with neratinib

Posted on March 29, 2019 by kuhnadmin

USC scientists Dr. Stephanie Shishido will present results from a small cohort study from a clinical trial in which metastatic breast cancer patients with a rare form of the disease (ERBB2 mutated, HER2 non-amplified) were treated with the combination of Neratinib and Fulvestrant. This work focuses on the use of a blood sample for a …

Continue reading “#AACR19: Morphologic and genomic characterization of circulating tumor cells in patients with ERBB2 mutant HER2 non-amplified metastatic breast cancer treated with neratinib”

#AACR19: Genomic characterization of circulating tumor cells in de novo metastatic prostate cancer

Posted on March 29, 2019 by kuhnadmin

Presenters: Shoujie Chai1, Paymaneh D. Malihi1, Ana M. Apariciop2, Brian F. Chapin2, Matthew Lin1, Ryan Storgard1, Carmen Ruiz Velasco1, Anand Kolatkar1, James Hicks1, Peter Kuhn1. 1University of Southern California, Los Angeles, CA; 2The University of Texas MD Anderson Cancer Center, Houston, TX Abstract: Background: The absence of biomarkers that identify clinically meaningful biological subsets of prostate cancer …

Continue reading “#AACR19: Genomic characterization of circulating tumor cells in de novo metastatic prostate cancer”

#AACR19: Genomic cfDNA analysis of aqueous humor in retinoblastoma (RB) predicts eye salvage

Posted on March 29, 2019 by kuhnadmin

Presenter: Liya Xu1, Jesse L. Berry2, Irsan Kooi3, A Linn Murphree2, Rishvanth K. Prabakar1, Mark W. Reid4, Kevin Stachelek4, Bao Han A. Le2, Lisa Welter1, Rima Jubran4, Thomas C. Lee2, Jonathan W. Kim2, Peter Kuhn1, David Cobrinik2, James B. Hicks1.  1University of Southern California, Los Angeles, CA; 2Children’s Hospital Los Angeles and the USC Roski Eye …

Continue reading “#AACR19: Genomic cfDNA analysis of aqueous humor in retinoblastoma (RB) predicts eye salvage”

Postdoctoral Position in Precision Oncology Data Science

Posted on February 1, 2019 by kuhnadmin

Official File: Biotech Data Scientist Postdoc – Job Posting The Kuhn-Hicks laboratory at USC is a leader in mathematical oncology for predictive mapping of cancer progression and treatment response. The laboratory uses clinical, demographic, and single cell morpho-proteo-genomic data to build predictive models to aid in improving patient care and outcomes. Our rapidly growing team is …

Continue reading “Postdoctoral Position in Precision Oncology Data Science”

Should Research-grade Genomic Data be Returned to Patients?

Posted on January 22, 2019 by kuhnadmin

While literature in clinical practice and patient rights suggests that study participants should have access to their genomic data, IRBs do not currently include mechanisms to facilitate effective and ethical collection of patient data across institutions and dissemination back to patients. Professor Kuhn and colleagues discuss the rights of patients to access their genomic data and …

Continue reading “Should Research-grade Genomic Data be Returned to Patients?”